A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Bb 2121 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors bluebird bio; Celgene Corporation
- 13 Sep 2017 According to bluebird bio media release, first patient has been treated for part B expansion cohort study of the trial.
- 25 Jun 2017 Updated results (n=11;data cut off: 18 Nov 2016) assessing safety and preliminary efficacy presented at the 22nd Congress of the European Haematology Association.
- 19 Jun 2017 According to a Celgene Corporation media release, data from this trial will be presented at the 22nd European Hematology Association annual meeting 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History